Descrizione del progetto
Gli organoidi pancreatici potrebbero contribuire ad accelerare lo sviluppo di trattamenti efficaci per il cancro al pancreas
Sebbene il cancro al pancreas sia l’undicesimo cancro per diffusione nel mondo, è la settima causa di morte per cancro a livello globale. Nonostante i progressi nella diagnosi e nella gestione del cancro al pancreas, il tasso di sopravvivenza a cinque anni rimane ancora al di sotto del 10 %. La rete di formazione PRECODE si avvale di una tecnica di nuova concezione, l'autoassemblaggio di tessuti funzionali che mimano l’organo in vitro, per accelerare lo sviluppo di farmaci per questa malattia letale. Giovani ricercatori stanno perfezionando le loro capacità nella coltivazione e nella manipolazione degli organoidi pancreatici per comprendere meglio la progressione della malattia. In definitiva, l’utilizzo di organoidi pancreatici sviluppati dalle cellule del paziente potrebbe portare ad una medicina personalizzata mirata, specifica e altamente efficace contro il cancro al pancreas.
Obiettivo
The PRECODE Network (PancREatic Cancer OrganoiDs rEsearch) central mission is to establish pancreatic organoid research firmly in the European Union, by training the next generation of creative and innovative researchers in pancreatic cancer. This will be done through a shared doctorate program of excellence that fulfils the three “I”: international, interdisciplinary and intersectorial. Organoids can be viewed as small micro-organs which can recapitulate the organization and the function thereof. As micro-organs organoids can be used to reduce animal experiments and help to reach 3R goals. Organoids from pancreatic cancer will help us to learn which drugs might help in the therapy of this terrible disease. They can be isolated from a variety of clinical sources with minimal material needed. This makes them a perfect tool for precision medicine. Sequencing, metabolomics and high throughput in vitro experiments to deduct the best possible drug combination fit hand in glove with this approach. Training of ESRs will be achieved by e-learning, workshops and secondments. They will earn to cultivate and manipulate organoids as well as cutting edge molecular biology techniques. Therefore our work group consists of 15 beneficiaries and 7 partner organization (including three patient advocate groups from Sweden, Italy and Germany) to develop those technologies and to train ESRs in their application. PRECODE will therefore connect the concepts of investigation, education and innovation establishing a capacitation for the ESRs that goes beyond the state of the art and that will allow them to improve their competences and their professional career at the same time that we advance towards innovation in the field of pancreatic cancer research.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinatore
91054 Erlangen
Germania